trial · primary record
SCTA02A
Hepatitis B
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2027-12 |
| Primary endpoint | Incidence and severity of treatment-related adverse events (TRAEs) after administration.Maximum tolerated dose(MTD) |
| Registry ID | NCT07903831 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:05.983Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07903831
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.